Puma Biotechnology
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial ...
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00398567
- Locations
- πΊπΈ
Duke University, Duke University Medical Center, Durham, North Carolina, United States
πΊπΈLAC/USC Medical Center, USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈUniversity of Maryland, University of Maryland Medical Center, Baltimore, Maryland, United States
A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00397046
- Locations
- π―π΅
Shizuoka Cancer Center, Shizuoka, Japan
π―π΅The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
HKI-272 Ketoconazole Drug Interaction Study
- Conditions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00380328
Study Evaluating HKI-272 Administered to Healthy Subjects
- Conditions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00366600
- Locations
- πΊπΈ
Northwest Kinetics, Tacoma, Washington, United States
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT00300781
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈBoston University Medical Center, Boston, Massachusetts, United States
πΊπΈThe Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT00266877
- Locations
- πΊπΈ
University of Minnesota, Minneapolis, Minnesota, United States
πΊπΈCase Western Reserve University, Cleveland, Ohio, United States
πΊπΈVanderbilt University Medical Center, Nashville, Tennessee, United States
Study Evaluating HKI-272 in Tumors
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00146172
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
πΊπΈH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
πΊπΈThe Cleveland Clinic Foundation Taussig Cancer Center, Cleveland, Ohio, United States